Objective: To analyze the effects of intravitreal injection of ranibizumab combined laser for treating macular edema secondary to central retinal vein occlusion. Methods: 67 macular edema secondary to central retinal vein occlusion patients were randomly divided into A group (n=33) and B group (n=34). The patients in A group were treated with laser only; the patients in B group were treated with intravitreal injection of ranibizumab combined laser. The treatment effects, as well as the best corrected visual acuity and central foveal thickness before and after treatment were compared. Results: The total effective rate of B group was 93.48% (43/46), which was obviously higher than A group (P<0.05). The best corrected visual acuity of patients in B group was obviously higher than that before treatment, the central foveal thickness was obviously lower (P<0.05). Moreover, the corrected visual acuity and central foveal thickness of patients in B group after treatment were obviously better than A group after treatment (P<0.05). Conclusions: Treating macular edema secondary to central retinal vein occlusion with intravitreal injection of ranibizumab combined laser can improve the visual acuity and central foveal thickness effectively, so it is worthy of clinical promotion.